Legal & General Group Plc Has $12.46 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Legal & General Group Plc lessened its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 5.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 149,161 shares of the biopharmaceutical company’s stock after selling 8,681 shares during the period. Legal & General Group Plc owned 0.14% of Intra-Cellular Therapies worth $12,458,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. M&T Bank Corp lifted its holdings in Intra-Cellular Therapies by 2.2% during the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after acquiring an additional 141 shares during the period. CIBC Asset Management Inc boosted its holdings in Intra-Cellular Therapies by 5.3% in the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock valued at $247,000 after acquiring an additional 150 shares during the last quarter. Pallas Capital Advisors LLC increased its position in Intra-Cellular Therapies by 6.4% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock valued at $266,000 after purchasing an additional 192 shares during the period. Finally, Arizona State Retirement System raised its holdings in Intra-Cellular Therapies by 0.8% during the 4th quarter. Arizona State Retirement System now owns 27,565 shares of the biopharmaceutical company’s stock worth $2,302,000 after purchasing an additional 206 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

NASDAQ:ITCI opened at $131.87 on Thursday. Intra-Cellular Therapies, Inc. has a one year low of $64.09 and a one year high of $131.98. The company has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. The firm has a 50-day moving average of $130.58 and a 200-day moving average of $105.16.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to the consensus estimate of $205.08 million. On average, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ITCI. Piper Sandler reiterated a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. StockNews.com assumed coverage on Intra-Cellular Therapies in a research report on Sunday. They issued a “hold” rating for the company. Cantor Fitzgerald restated a “neutral” rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 target price (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Finally, Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 13th. Eleven analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Intra-Cellular Therapies has an average rating of “Hold” and an average target price of $106.23.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.